Latest From Oxagen Ltd.
Novartis’s investigational oral therapy for asthma fell at the first Phase III hurdle but pivotal studies in severe disease will be key to prospects.
UK-based Redx Pharma has promoted Dr Richard Armer to chief scientific officer and Phil Tottey to chief financial officer.
The pharmaceutical division of Teijin has acquired rights in Japan to Pulmagen Therapeutics' lead CRTh2 antagonist ADC3680, which it will develop initially for bronchial asthma.
The European venture capital firm Wellington Partners has completed the first closing of its fourth life sciences fund with initial commitments of €70 million from investors. At €120 million, the final target size of the fund is expected to exceed that of Wellington Partners III Life Science Fund, which raised €78 million.
- Therapeutic Areas
- Immune Disorders
- Respiratory, Pulmonary
- Western Europe
- Parent & Subsidiaries
- Oxagen Ltd.
- Senior Management
Mark Payton, PhD, CEO
Mike Perkins, MD, Dir., Drug Dev.
Paul Foster, Head, Fin. & Admin.
- Contact Info
Phone: (44) 1235 443300
91 Milton Park
Abingdon, OX14 4RY
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.